Is MEDVi Legit? What 11 Record Checks Show in 2026

By the Weight Loss Provider Guide Editorial Team
First published: April 22, 2026 · Last verified: August 6, 2026

Affiliate disclosure, before you read another word: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. Some links on this page earn us a commission if you use them. That includes MEDVi. It changes nothing about the FDA record, the BBB file, MEDVi's prices, or MEDVi's own written policies below — and you'll notice pretty quickly that we're not handing you a big orange button and calling it a day.

The short answer: is MEDVi legit?

Yes — MEDVi is a real, traceable operating telehealth platform. It is not a fake storefront. But “real” and “safe to hand your health information and credit card” are two different questions, and MEDVi's own public record is where the second one gets complicated.

Here is what we verified on August 6, 2026. The FDA sent MEDVi, LLC a warning letter on February 20, 2026 over misleading marketing of compounded semaglutide and tirzepatide. We found no published close-out letter. The Better Business Bureau gives MEDVi an F, citing 682 complaints and 100 unanswered complaints. MEDVi requires cancellation at least 72 hours before the next billing date. Its Terms also try to cap MEDVi's liability for claims under those Terms at $100, to the extent the law allows.^{1 2 3 4}

The price is not as simple as one number. MEDVi's standard semaglutide page shows $179 for the first billing cycle and $299 for refills. A separate “price locked” page shows $116 for semaglutide and $166 for tirzepatide in its offer cards — while the FAQ on that same page says $166 and $199. MEDVi's Terms say the final charge can vary with the prescription and pharmacy. The ad is not the contract. The exact checkout is the number that matters.^{5 6 4}

The honest version: MEDVi is real. The FDA warning is real. The complaint record is real. The written billing rules are real. You can still decide MEDVi is the right tradeoff for you — but only after you know the exact medication, pharmacy, recurring price, billing date and cancellation deadline before you pay.

That's what this page is for.

The 20-second verdict

Here's the one flaw we'd flag before anything else

MEDVi's main cash-pay products are compounded medications, not FDA-approved brand-name drugs, and MEDVi's affiliated medical groups are described as out of network. If you want only an FDA-approved medication or you want someone to handle insurance and prior authorization, stop here and go to FDA-approved GLP-1 options with insurance support — Ro is a better fit for that job.

But here's the flip side, and it's the whole reason MEDVi exists: a cash-pay route removes the prior-authorization wait, the coverage denial and the pharmacy-benefit fight. You answer the intake questions, an affiliated clinician reviews your information, and that clinician decides whether a prescription is appropriate.

MEDVi does not, however, show one clean universal public price that you can assume will apply to you. Its own pages conflict. So the tradeoff is not “one flat price and no friction.” The honest tradeoff is less insurance friction, but more responsibility on you to save the exact checkout offer and manage the subscription rules.

So the question isn't “is MEDVi good or bad.” It's “is MEDVi's tradeoff the right tradeoff for you?” Let's go find out.

If MEDVi still sounds like your lane: check MEDVi's live offer and eligibility. Before you enter payment details, screenshot the medication, first charge, recurring charge, renewal date and cancellation terms shown to you.

What we actually verified about MEDVi

We checked MEDVi's legal identity, platform role, named clinical network, current pharmacy list, FDA record, live public prices, cancellation policy, contract terms, review profiles and relevant public records. We did not enroll, pay, receive medication, inspect a shipment or test a vial.

We didn't take any review site's word for everything — including our own older pages. Here's exactly what we opened and what each source can prove.

The MEDVi 11-point legitimacy and checkout-risk audit

Sources: MEDVi Terms, MEDVi cancellation policy, MEDVi standard GLP-1 page, MEDVi price-lock page, FDA Warning Letter #721455, BBB, Trustpilot, and ConsumerAffairs.

What we could not verify — and we're telling you instead of guessing

This part matters as much as the table above.

• Which clinician you will get. The named network is public; the assigned person is patient-specific.
• Which pharmacy will fill your order. MEDVi names three current partners, but that does not tell you which one will receive your prescription.
• The exact product in your order. “Semaglutide,” “tirzepatide,” “tablet” and “injection” are not enough. You need the exact name, formulation, concentration and pharmacy.
• The exact price at your checkout. MEDVi's own pages conflict, and its Terms allow the charge to vary with the medication and pharmacy.
• The exact billing cadence. We verified the 72-hour cancellation rule, but we did not find one current official page that clearly establishes a universal 28-day or calendar-month schedule for every offer.
• Which states each product is available in. MEDVi's Terms say services are available in certain states and direct people to support for current availability.
• Whether FDA has closed the warning-letter matter since our check. We found no published close-out letter as of August 6, 2026. That database can change.
• Whether a reviewer's result is typical. Reviews can show service themes. They cannot establish what will happen to another patient.
• The identity, strength, sterility or storage history of a specific shipment. We did not receive or test one.

Everything below is built from documents you can open yourself.

Is MEDVi a scam?

No. MEDVi is a real operating platform with a traceable legal entity, a public address, published Terms, named clinical networks, named pharmacy partners and a large public review footprint. But a real company can still have serious billing, service, contract and regulatory problems. “Not a scam” is the start of the answer, not the end.

This distinction is the single most useful thing on this page, so let's be precise about it.

A fake storefront hides who it is, takes payment and gives you no clear business, medical or pharmacy chain to check.

MEDVi is different. MEDVi, LLC appears under the same Newark, Delaware address in its own Terms, the FDA warning letter and the BBB profile. MEDVi publishes the outside networks and pharmacies it says may touch an order. That is enough to answer the narrow “is there a real company here?” question.^{4 1 2}

It is not enough to answer the question you actually care about: “Will this be the right, fair and medically appropriate route for me?”

Three things about MEDVi are genuinely solid:

• A traceable legal identity. The same company name and address appear across independent official records.
• A disclosed care chain. MEDVi names outside clinical networks and three current pharmacy partners rather than pretending the website itself does every job.
• Public written policies. The Terms, cancellation policy and privacy materials are available to read before enrollment.

Three things are genuinely not clean:

• A February 2026 FDA warning letter with no published close-out found during this review.
• An F-rated BBB profile with 682 complaints and 100 unanswered complaints.
• Public price conflicts and contract terms that give MEDVi broad protections while putting the billing-calendar work on the customer.

That is not a scam verdict. It is a real-company, read-the-contract verdict.

Everything from here is documents. Let's go.

Why did the FDA send MEDVi a warning letter?

On February 20, 2026, FDA issued Warning Letter #721455 to “MEDVi, LLC dba MEDVi.” FDA said the reviewed website used product images and equivalence language that falsely or misleadingly suggested MEDVi was the compounder and that its compounded drugs had been FDA-approved or evaluated. We found no published close-out letter as of August 6, 2026.¹

What a warning letter actually is

Plain version: it is FDA telling a company to correct stated violations and warning that failure to do so may lead to enforcement.

It is not a criminal conviction. It is not a product recall. It is not a court judgment. Warning letters are advisory notices, but they are not casual suggestions. The MEDVi letter says failure to correct the issues may lead to legal action, including seizure or injunction.¹

What the letter did not say

Don't let anyone — including a competitor's page — turn it into something it was not.

• It did not announce that every MEDVi medication was unsafe.
• It did not announce a recall.
• It did not shut MEDVi down.
• It did not identify a contaminated lot.
• It did not decide that every MEDVi customer was harmed.

The documented problem was marketing and misbranding. That still matters because a customer needs to know who made the drug and whether the finished product went through FDA approval.

Context that's fair to MEDVi

MEDVi was not the only telehealth company warned. On March 3, 2026, FDA announced warning letters to 30 telehealth companies over illegal or misleading marketing of compounded GLP-1 products.⁷

That makes the action part of a broad industry sweep. It does not erase MEDVi's own letter.

MEDVi's explanation — and the record beside it

MEDVi's public response says the reviewed medvi.io material came from an affiliate-controlled website using outdated copy and that the affiliate removed the material. MEDVi also said it had found potentially AI-generated practitioner advertising connected to affiliates and changed its practices.⁸

Here is the part that still matters: FDA addressed the letter to MEDVi, LLC dba MEDVi at the same Newark address MEDVi uses in its own Terms. MEDVi's explanation is part of the record. So is the FDA letter.

We're not asking you to choose a villain. We're showing you both documents and letting you weigh them.

What MEDVi changed on its current site

We compared the specific issues named by FDA with MEDVi's live public pages on August 6, 2026.

The current site addresses the specific wording and disclosure problems named in the warning letter. That is a fair point in MEDVi's favor. Only FDA can decide whether MEDVi's response is adequate and whether the matter should receive a formal close-out.

→ Want the full regulatory breakdown? Read Is MEDVi's GLP-1 FDA approved?.

Is MEDVi FDA approved?

The FDA does not approve telehealth platforms. It approves specific drug products for specific uses. MEDVi's compounded semaglutide and compounded tirzepatide products are not FDA-approved finished drugs. A named brand product offered through MEDVi can be FDA-approved — but only the exact branded product, not the platform or a compounded substitute.

This trips up almost everyone, so here it is as a simple table.

FDA's current labels confirm that Wegovy includes an oral semaglutide tablet, Foundayo is an oral orforglipron product first approved in 2026, and Zepbound is tirzepatide by injection.^{9 10 11}

What “compounded” means: a pharmacy prepares a medication for a patient under compounding law and a prescription. Compounding is a real part of medicine. But the finished compounded drug does not go through the same FDA approval review as a branded approved product.

A pharmacy license is not the same as an approved drug. A license can tell you that a pharmacy is authorized to operate. It does not turn the finished compounded product into an FDA-approved one.

The one question to ask before payment

Copy this word for word:

“If I am approved, will my prescription be for a compounded product or a named FDA-approved brand, what is the exact formulation, and which pharmacy will fill it?”

If you cannot get a clear written answer before the order moves forward, pause. Do not fill the gap with an assumption.

Who actually prescribes and fills your MEDVi prescription?

Not MEDVi itself. MEDVi's Terms say the platform does not practice medicine and is not a pharmacy. MEDVi currently names CareGLP Affiliated P.C.s and OpenLoop Health for medical care, plus Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding as pharmacy partners. The assigned clinician and pharmacy can vary by patient and order.^{4 12}

The chain, in plain terms

You → MEDVi (website, intake, coordination and payment) → OpenLoop or CareGLP (the clinician who decides whether to prescribe) → one assigned pharmacy (the party that prepares or dispenses the prescription) → your door.

Why this matters: different parties handle different duties. If the issue is a clinical decision, the clinician is the right contact. If it is the physical medication, the dispensing pharmacy matters. If it is a subscription charge, MEDVi's billing and cancellation rules matter.

Also worth knowing: payment does not guarantee a prescription. MEDVi's policy says an OpenLoop clinician reviews the person after checkout and keeps the final prescribing decision. MEDVi says it refunds customers who are medically disqualified.³

The pharmacy finding we haven't seen explained clearly elsewhere

Two public facts belong in the same section.

Fact one: A federal case filed in Delaware in November 2025 names OpenLoop Health, Triad Rx Buyer LLC and Triad Rx Inc. as defendants. The complaint alleges that compounded oral tirzepatide sold to the plaintiff lacked an adequate absorption pathway and includes a RICO claim. The defendants moved to dismiss or, in the alternative, compel arbitration. The public docket we reviewed did not show a merits judgment. MEDVi is not named as a defendant in that case.^{13 14}

Fact two: MEDVi's current public pages name OpenLoop Health and Triad Rx in its own care and pharmacy chain.¹²

We want to be careful here. The complaint concerns an oral tirzepatide product, not every MEDVi medication and not MEDVi's compounded injections. An allegation is not a finding.

What we're saying is simpler: you should know the exact pharmacy and formulation attached to your own prescription, then check what is publicly on the record about both.

The Belmar problem — including on one of our own older pages

Many MEDVi reviews still identify Belmar Pharma Solutions as MEDVi's pharmacy and use Belmar's history as a trust signal.

Belmar is not on MEDVi's current public partner-pharmacy list. The current list names Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding.¹²

We'll own our share of that. An older page on one of our sites repeated the Belmar claim, and it needs correction. A current review should use the current list, then tell the reader to verify the pharmacy assigned to the actual order.

A small disclosure-quality detail we also found: MEDVi's footer listed RedRock Pharmacy twice with two different phone numbers when we checked it. That is not proof of a safety problem. It is another reason to verify the exact pharmacy contact information on your own order.

How to check your own clinician and pharmacy

Once they are assigned:

1. Ask for your clinician's full legal name and the state license used for your visit.
2. Search that name on the state medical or nursing board website.
3. Confirm that the license is active and look for any public discipline.
4. Ask which specific pharmacy received your prescription.
5. Search that pharmacy on its home-state board of pharmacy site.
6. Confirm that it may ship into your state for the type of prescription involved.
7. When the package arrives, check that the pharmacy name and product information match what you were told.
8. If the label, concentration, package or instructions are unclear, contact the prescriber and pharmacy before using it.

→ Not comfortable with this care chain? That's a completely reasonable line to draw. Use the free matching tool to find a path that fits your comfort level.

What does MEDVi really cost after the first month?

There is no single public MEDVi price we can honestly promise applies to every reader. MEDVi's standard semaglutide page says $179 for the first billing cycle and $299 for refills. A separate official “price locked” page displays lower figures that conflict with its own FAQ. MEDVi's Terms also allow the final charge to vary with the prescription and pharmacy.^{5 6 4}

The official-price conflict

This is the strongest price finding on the page because all four numbers come from MEDVi's own current pages.

The ad is not the contract. The checkout is.

Do not ask only, “What does MEDVi start at?” Ask:

• What comes out of my card today?
• What is the next charge?
• What date will it happen?
• Is that amount locked for my dose and formulation?
• Is the billing cycle monthly, every 28 days or something else?
• What happens if the pharmacy or prescription changes?

The standard $179-to-$299 scenario

The table below keeps the original standard-page math because it is still useful — as long as it is labeled correctly.

Read the label carefully: these are totals for that number of billed cycles under the standard $179/$299 page. They are not a promise that your offer, formulation, dose or calendar-year total will match.

Do not use a “13 charges per year” estimate unless MEDVi shows you a 28-day cadence in writing. We could not verify one universal 28-day billing schedule from a current primary MEDVi source. Ask for the exact next billing date and cycle length at checkout.

Brand-name options have two separate costs

MEDVi's current price-lock page also displays Wegovy tablet, Wegovy injection and Zepbound injection cards using a $99 membership plus medication cost structure. The medication price is separate, and availability can change.⁶

That is a different commercial path from a bundled compounded offer. Do not compare “$99” with “$299” until you have added the brand medication cost.

Insurance, HSA and FSA

MEDVi's Terms describe the affiliated medical entities as out of network and warn that prescriptions or laboratory services may not be covered. Treat the main MEDVi compounded path as cash-pay unless your written offer says otherwise.⁴

MEDVi markets HSA/FSA payment eligibility. That is a provider-stated payment feature, not a promise that your specific plan administrator will approve every charge. Save the prescription, receipt and itemized documentation, and check your own plan rules.¹²

MEDVi price and cancel-by worksheet

Use the exact numbers from your checkout — not the numbers in an ad.

→ If you have insurance, check it before you spend a dollar on a cash-pay program. Check GLP-1 insurance coverage with Ro — free, no card required. Ro currently checks Ozempic, Wegovy and Zepbound pen coverage; coverage is not guaranteed.¹⁵

For the full price-owner page, see MEDVi cost and current offer conflicts.

The MEDVi cancellation trap — and exactly how to avoid it

MEDVi requires a cancellation request to be received at least 72 hours before the next billing date. Its official policy directs customers to email or use patient-portal chat and does not describe a self-serve cancellation button. If the request arrives too late, the next cycle may be charged, and monthly charges are generally not refunded for the current or prior month.³

Billing, cancellation and refund problems recur across MEDVi's negative reviews. The useful part is that MEDVi's own written policy explains many of the situations people describe.

The refund-clause decoder

About the “money-back guarantee”

Several review pages use a broad money-back-guarantee claim as proof that MEDVi is safe to try. MEDVi's current written policy is narrower.

The policy lists these main refund situations:

1. Cancellation within the first 72 hours of the subscription term when no services have been received.
2. Medical disqualification by the healthcare provider.
3. For a plan charged two or more months at once, the unused months for which medication was not shipped.
4. Damaged or incorrect medication may be replaced, with refunds considered under the stated policy.

There is no current written promise that simply failing to lose weight produces a full refund. MEDVi's separate Terms also say medical consultation fees are not refundable and describe sales as final, while the cancellation policy lists the exceptions above.^{3 4}

Two MEDVi documents need to be read together. Do not rely on a third-party summary of a “guarantee.”

Your copy-and-paste cancellation email

Send this to hello@medvi.org, the address named in MEDVi's current cancellation policy. Send the same request through portal chat on the same day.

Subject: Cancellation request — effective immediately

I am canceling my MEDVi subscription effective immediately. This request is submitted on [DATE] at [TIME], which is more than 72 hours before my next billing date of [DATE AND TIME].

Please confirm in writing: (1) that my cancellation is processed, (2) my final service date, (3) whether any medication order is already pending, and (4) that no further charges are scheduled to my payment method.

[Your full name, account email and other account identifier MEDVi asks for]

Screenshot the sent email. Screenshot the portal message. Save the reply, billing history and current policy. A timestamp does not guarantee that a card dispute will be decided in your favor, but it gives you evidence of what you asked MEDVi to do and when.

The 30-day arbitration choice almost nobody notices

MEDVi's Terms contain a mandatory-arbitration clause and class-action waiver for covered disputes. They also give the customer 30 calendar days after first accepting the Terms to reject that arbitration clause by emailing help@medvi.org with the required identifying information and a clear opt-out statement.⁴

Opting out does not “keep every legal option open” in every situation, and this page is not legal advice. It does mean the arbitration clause in these Terms says it will not bind a person who completes the stated opt-out correctly and on time, subject to applicable law and any other agreement.

If that choice matters to you, read the current clause yourself and decide inside the stated window.

The $100 clause that reframes the whole page

MEDVi's Terms say that, to the extent permitted by law, MEDVi's total liability for claims under the Terms will not exceed $100.⁴

Read that beside the standard-price table. Twelve billed cycles under the $179/$299 scenario total $3,468. MEDVi's contract attempts to cap its own liability under those Terms at a small fraction of that amount.

That does not mean no person could ever recover more than $100. The clause itself is limited by applicable law, and some claims or jurisdictions may be treated differently. But the clause is still a material term a reasonable customer should see before accepting it.

We're not going to tell you what legal choice to make. We're going to tell you the clause is there, what it says in plain English and where to read it.

→ If managing a 72-hour deadline by email and chat is a dealbreaker — and honestly, that's fair — see GLP-1 providers with easier cancellation.

Why does MEDVi have an F from the BBB when Trustpilot says 4.4?

Because the three platforms collect and score different things. Trustpilot shows 4.4/5 from 14,339 reviews and includes invited and unprompted reviews. ConsumerAffairs shows 3.3/5 from 2,193 reviews. BBB gives MEDVi an F based on its rating factors and complaint handling, including 682 complaints and 100 unanswered complaints. None of those numbers cancels the others out.^{16 17 2}

The three-platform reconciliation

What the “barbell” tells you

Trustpilot's 80% five-star and 11% one-star split is more useful than the 4.4 average by itself.

This is not a bland middle. Smooth experiences are common on that platform, and severe dissatisfaction is not rare. Some people describe an easy intake, kind staff and helpful support. Others describe billing, cancellation, refund, shipment or communication problems.

Do not turn that into “MEDVi is two different companies” as a factual claim. It is one company producing sharply different reported experiences. Understanding the billing rules can prevent one common kind of surprise, but it cannot guarantee a smooth clinical, pharmacy or support experience.

Do not confuse MEDVi with MEDvidi

MEDVi is the Newark, Delaware telehealth platform discussed here. MEDvidi is a separate online mental-health business with a different name, location and service. When checking a complaint or profile, verify the spelling and make sure you are looking at MEDVi's Newark, Delaware record.

What real customers say — both sides

Real, attributed and labeled with how the platform says each review was collected.

“Easy to navigate the website and the provider was kind.”
— Ashley Selix, Trustpilot, invited five-star review, August 5, 2026

“The reorder process is simple and the support is very helpful.”
— Thomas, ConsumerAffairs verified purchase, May 9, 2026

“The subscription service is hard to discontinue.”
— soipr, Trustpilot, unprompted two-star review, May 12, 2026

Sources: Trustpilot and ConsumerAffairs.

Please read these for what they are. They are individual service experiences. They do not prove a medication is safe or effective. They do not tell you what result you will get. A negative review is an allegation, not a formal finding. We use reviews to identify questions and recurring friction — not to make medical claims.

Can you trust MEDVi's before-and-after photos?

Do not use MEDVi's photos as proof of a medical result or even proof that the pictured person is a patient. MEDVi's own live disclaimer says website materials may be generated or enhanced with artificial intelligence, people in advertising may be actors or models, and testimonial images may use models for privacy.¹²

That disclaimer is live on MEDVi's own site. We did not pull it from an old archive.

MEDVi's April 2026 public response also says the company became aware of potentially AI-generated practitioner advertising tied to affiliates and changed its practices.⁸

What you should actually take from this

Not panic. A rule:

Do not judge any online weight-loss program by transformation photos, smiling clinician headshots or a polished ad. Those materials can be edited, modeled, licensed or AI-generated.

Judge the program by what is harder to fake:

• The legal entity.
• The exact clinician.
• The exact pharmacy.
• The medication label.
• FDA records.
• State-license records.
• Written prices.
• Cancellation and refund terms.
• What the company does after a documented problem.

That is the entire reason this page exists.

Is MEDVi being sued?

Yes. A federal case against MEDVi is publicly docketed in California, and a separate Delaware case names two current parts of MEDVi's disclosed care chain — OpenLoop Health and Triad Rx — as defendants. A filed complaint is one side's allegation, not proof, and the dockets we reviewed did not show a judgment establishing liability on the claims discussed here.^{18 13 14}

Say it clearly: neither table row is a finding that MEDVi or its partners did what a plaintiff alleges. Companies can win, settle or obtain dismissal. The responsible use of a lawsuit on this page is to tell you what was filed, who was named, what product was involved and whether a court has reached the merits.

Also remember the arbitration section above. MEDVi's Terms contain a class-action waiver and a 30-day opt-out for the arbitration clause. Read the current version rather than relying on a review page's summary.

Are MEDVi's tablets and injections the same kind of risk?

No. MEDVi's compounded tablets and compounded injections are all non-FDA-approved finished products, but the practical questions differ by format. Oral tirzepatide has a specific absorption question and active litigation around one formulation. Compounded injections have their own FDA-documented risks, including dosing errors, concentration differences and shipping or temperature problems across the broader market.^{13 14 19}

This is the product decision worth slowing down on.

The format map nobody else gives you in one place

Why an oral peptide needs a real answer

Semaglutide and tirzepatide are peptides. Oral delivery is not as simple as putting an injectable ingredient into a tablet. The FDA-approved Wegovy tablet uses a specific approved formulation. No oral tirzepatide product is FDA-approved as of August 6, 2026.^{9 11}

The Delaware complaint's central allegation is that the compounded oral tirzepatide product at issue lacked an adequate way to be absorbed. That is an allegation, not a scientific finding by the court.^{13 14}

Compounded injections are not the “risk-free standard”

The original draft treated injections as the standard format and put nearly all product concern on tablets. That was too simple.

FDA has reported dosing errors with compounded injectable semaglutide, including errors tied to different concentrations, syringe units and unclear instructions. FDA has also warned about compounded GLP-1 shipments arriving warm and about products with fraudulent labels or questionable ingredients.¹⁹

The practical lesson is not “tablet bad, injection safe.” It is:

• Confirm the exact product and formulation.
• Confirm the exact pharmacy.
• Confirm the concentration and dose in both milligrams and syringe units when relevant.
• Get written instructions.
• Inspect the shipment and label.
• Contact the prescriber and pharmacy before using anything unclear.

What to ask your prescriber

If you are considering a compounded oral product, ask:

“What exact formulation and absorption system does this product use, what evidence supports that finished formulation, and which pharmacy prepares it?”

If you are already taking a prescribed product, do not stop or change it based only on an article. Contact the prescriber who knows your history and ask the question directly.

→ If the whole reason you wanted a tablet is that you do not want an injection, that is a real preference — and there are now FDA-approved oral weight-management options. Compare your FDA-approved and cash-pay paths, or see the Ro option in the alternatives table.

Was your information in the OpenLoop data breach?

Being a MEDVi customer does not prove your information was in the breach. OpenLoop Health — one of MEDVi's current named clinical networks — reported unauthorized access to certain systems from January 7 to January 8, 2026. HHS's breach listing was reported as affecting 716,000 people, but only OpenLoop can confirm whether a specific person's information was involved.^{20 21 12}

OpenLoop's California notice says the information involved varied by person. It says the incident did not involve access to the person's electronic health record, Social Security number or financial-account information. OpenLoop said it was not aware of misuse when it issued the notice and offered one year of identity and credit monitoring to notified people.²⁰

What to do if you used MEDVi or received care through OpenLoop

1. Look for a notice from OpenLoop. Do not assume you were included just because MEDVi names OpenLoop.
2. If you received a notice, read the exact data fields listed for you. The information varied by person.
3. Use the monitoring service if your notice still allows enrollment or contact OpenLoop for current help.
4. Consider a credit freeze based on your situation. It is a personal risk decision, not something every MEDVi customer automatically needs.
5. Watch for targeted phishing. A message that knows your provider or medication can still be fraudulent.
6. Contact OpenLoop patient support if you need confirmation. Do not send sensitive information to an address or number taken from an unsolicited message.

One more thing worth reading: MEDVi's Terms contain a broad license covering data a user submits to the platform. That clause does not erase separate privacy, health-data or legal duties, and this page is not interpreting its full legal reach. Read it beside MEDVi's current privacy and health-data policies before submitting sensitive information.⁴

Is compounded semaglutide even legal in 2026?

Yes, compounding can still be legal in 2026, but the broad shortage-based window for routine copies of semaglutide and tirzepatide has closed. Patient-specific compounding may continue when the prescription and pharmacy meet the applicable federal and state rules, including the “essentially a copy” limits. A lower price by itself does not establish a patient-specific clinical difference.²²

The timeline

Sources: FDA compounding clarification and FDA's April 30 proposal.

Two terms defined, since they are everywhere:

• 503A pharmacy — a state-licensed pharmacy or physician compounding for an identified individual patient under the conditions in federal law.
• 503B outsourcing facility — a facility registered with FDA that may compound in larger batches under a different federal framework and manufacturing requirements.

The “essentially a copy” rule, in plain words

A pharmacy generally cannot use compounding law as a permanent shortcut to mass-produce a cheaper copy of a commercially available FDA-approved drug.

Patient-specific compounding can still be permitted when the legal conditions are met. One important route involves a prescriber documenting that the compounded change produces a significant difference for the identified patient. The exact facts matter.

Examples might involve a needed dose or ingredient change that the approved product does not provide. Price alone is not the patient-specific clinical difference the rule asks for.

Adding vitamin B12 or another ingredient also does not automatically solve the “essentially a copy” problem. FDA's April 2026 clarification says the whole product and the documented patient need must be considered.²²

What this means for your supply

If you start a compounded program, ask two questions before you depend on it long term:

1. What patient-specific basis supports this prescription under current law?
2. What is my backup plan if the formulation, pharmacy or legal route changes?

That is not a reason to panic or to abruptly stop a prescribed medication. It is a reason to know what you are receiving and what you would do if access changes.

Who should use MEDVi — and who should skip it?

MEDVi may fit a cash-pay adult who understands that the main products are compounded, verifies the exact checkout terms, accepts the named care chain and will manage the billing dates deliberately. It is a poor fit for someone who wants only an FDA-approved product, needs insurance help, wants a clean complaint record or does not want to manage a 72-hour cancellation rule.

Find yourself in this table.

We'd rather lose you here than have you sign up for the wrong thing and blame the internet.

If MEDVi isn't your fit, what is?

It depends on what disqualified MEDVi. If you want an FDA-approved product or insurance help, Ro is the cleaner fit. If you still want a lower-cost compounded route, Embody currently advertises a lower starting price — but it also uses OpenLoop and a 72-hour cancellation rule, so it does not solve every MEDVi concern.^{23 24 25 26}

Most comparison tables stop at price and shipping. After everything above, the more useful columns are product status, insurance route, care network, price clarity and exit rules.

Why Ro is our pick if you want the approved medication

Ro's current pricing page lists FDA-approved Wegovy tablet, Foundayo tablet, Wegovy pen and Zepbound KwikPen cash-pay options. Its membership is $39 for the first month, then $149 on the monthly plan or as low as $74 per month with annual prepay; medication is charged separately.²³

Ro's free insurance checker currently checks coverage for Ozempic pen, Wegovy pen and Zepbound pen. It does not currently check insurance for Wegovy tablet, Foundayo or Zepbound KwikPen. For supported products, Ro says its insurance concierge can gather and submit prior-authorization paperwork, coordinate with the insurer and help with an appeal after a denial. Coverage is never guaranteed.^{15 24}

That makes Ro the better route when the reader's main objection is “I want the actual FDA-approved product” or “I need help testing my insurance before I pay cash.”

Why Embody is worth comparing — and where it does not fix MEDVi

Embody's current public page advertises compounded GLP-1 injections starting at $79 per month. Its policy allows cancellation through support or an online-account process if available, but still requires at least 72 hours before the billing date. Its site also names OpenLoop as the clinical network.^{25 26}

So Embody may solve a starting-price problem. It does not automatically solve a concern about OpenLoop, compounded medication or a 72-hour cancellation cutoff.

Two honest CTAs — pick the one that is actually you:

If you want an FDA-approved product or want to find out what insurance covers before spending cash:
Check your GLP-1 insurance coverage with Ro — free, no card required

If cash-pay compounding is still the route you want and the lower advertised starting price matters most:
Check Embody eligibility and current pricing

For a direct head-to-head, see MEDVi vs. Ro.

Your 11-point MEDVi before-you-pay checklist

Before you enter payment information with MEDVi — or any online GLP-1 program — you should be able to answer all 11 questions below. If the company cannot give you a clear written answer to one that affects your medication or money, that is not a paperwork gap. That is your signal to pause.

Print this. Screenshot it. Whatever works.

☐ 1. Exact medication. What is the full product name on the proposed prescription?

☐ 2. FDA status. Is it compounded, or is it a named FDA-approved brand?

☐ 3. Exact format and formulation. Injection or tablet? What concentration, ingredients and dose are being prescribed?

☐ 4. Prescriber. Who makes the decision, what license do they hold, and in which state?

☐ 5. Pharmacy. Which specific pharmacy will prepare or dispense and ship the order? Is its license active, and may it ship into your state?

☐ 6. State availability. Is this exact product and visit method available where you live today?

☐ 7. First charge. Exactly what amount comes out today, and what services or medication does it cover?

☐ 8. Recurring charge and cadence. Exactly what amount comes out next, on what date, and on a 28-day, monthly or other cycle?

☐ 9. Cancellation deadline. What exact date and time is 72 hours before the next billing event? Put a second reminder 24 hours earlier.

☐ 10. Refund and shipment rules. What happens if a clinician declines, nothing ships, the shipment is damaged, or you cancel after a charge?

☐ 11. Contract choice and proof. Save the Terms, price page, order screen and cancellation policy. Read the arbitration clause and decide whether to use the 30-day opt-out.

If you have read this whole page, understand the tradeoff and MEDVi still fits your situation, you are making an informed decision — and that is the only kind we care about.

See MEDVi's live offer and check if you qualify

Approval is not guaranteed. Confirm the exact medication, pharmacy, first charge, recurring charge and billing date before you pay — that is what the checklist is for.

Already signed up and worried? Here's what to do today

Don't panic, and don't stop or change a prescribed medication on your own. Do three things first: find the exact next billing date, send any cancellation request through the channels MEDVi's current policy names, and save proof. If the concern is the medication itself, call the prescriber or dispensing pharmacy before changing anything.

Nobody writes this section. Most pages answering “is MEDVi legit?” are written only for people who have not paid yet. So:

1. Do not stop or change the medication based only on an article. That is a medical decision. Contact the clinician who knows your history.

2. Find the exact next billing date and time. Do not assume it is always the same calendar day or a universal 28-day schedule. Use the portal, invoice or written confirmation.

3. Count back 72 clock hours. That is the deadline stated in MEDVi's current policy. Give yourself another day of buffer when possible.

4. Send the cancellation request in writing. Use hello@medvi.org and portal chat, as the current policy directs.

5. Save everything. The current policy, Terms, checkout screen, sent email, portal message, reply, billing history, tracking and pharmacy label.

6. If a charge posts after a timely written request: contact MEDVi in writing and ask for the reason. If it is not fixed, you can file a complaint on MEDVi's Newark, Delaware BBB profile and ask your card issuer about its dispute process. Your timestamped evidence may support the dispute; no article can promise the outcome.

7. If you are inside the 30-day Terms window: read the arbitration clause and decide whether to send the stated opt-out. This is a legal choice, not a medical one.

8. If you take a compounded tablet: ask your prescriber for the exact formulation, absorption method, evidence and pharmacy. Do not abruptly stop without clinical guidance.

9. If you received an OpenLoop breach notice: follow the notice, use any offered monitoring and contact OpenLoop with questions. Do not assume inclusion solely because MEDVi names OpenLoop.

10. If you want treatment to continue somewhere else: talk with the current or new clinician before creating a gap. The clinician may need to review your dose, time off treatment and side effects before deciding how to continue.

→ Find your next program with our free 60-second quiz.

Our final verdict: is MEDVi legit enough to consider?

Yes — MEDVi is legitimate in the narrow, accurate sense that it is a real, traceable operating platform with named clinical and pharmacy relationships and published policies. That does not erase the FDA warning, BBB F rating, public price conflicts, strict refund terms, arbitration language or the Terms' attempted $100 liability cap.

The case for considering MEDVi:

• A real legal entity whose name and address match across independent records.
• A disclosed care chain with named clinical networks and current pharmacy partners.
• A cash-pay route that avoids insurance prior authorization and denial delays.
• A standard semaglutide page that gives a usable $179/$299 scenario — as long as you verify your own offer.
• A large Trustpilot footprint with 80% five-star reviews over the last 12 months.
• Current site language that addresses the specific compounder and FDA-status issues named in FDA's warning letter.

The case against:

• February 2026 FDA warning letter; no published close-out found as of August 6, 2026.
• BBB F rating, 682 complaints and 100 unanswered complaints.
• Conflicting prices on MEDVi's own current pages.
• A 72-hour cancellation cutoff and limited monthly refunds.
• Mandatory-arbitration and class-action language unless the stated 30-day opt-out is used.
• Terms that attempt to cap MEDVi's liability under the agreement at $100 where the law permits.
• OpenLoop and Triad Rx — current parts of MEDVi's disclosed chain — are defendants in pending oral-tirzepatide litigation; MEDVi is not a defendant in that case.
• Tablets and injections carry different questions, and neither compounded format is FDA-approved as a finished drug.

Our editorial conclusion: MEDVi may be a reasonable commercial fit for a cash-pay adult who accepts a compounded route, verifies the exact formulation and pharmacy, saves the real checkout price and manages the billing dates deliberately. It is the wrong path for anyone who wants an FDA-approved product, insurance support, easy refunds, one clean public price or a clean regulatory and complaint record.

That is a commercial-fit conclusion. Whether any GLP-1 treatment is medically right for you is a decision only a licensed clinician can make, and no page on the internet — including this one — can replace that conversation.

MEDVi still fits after all of that?
Review MEDVi's live offer and check eligibility

Save the exact medication, pharmacy, recurring price, renewal date and cancellation terms before payment.

Frequently asked questions about whether MEDVi is legit

Is MEDVi a scam?

No. MEDVi is a traceable operating telehealth platform with a public legal identity, address, Terms, named clinical networks and named pharmacy partners. But a real company can still have serious billing, refund, service and regulatory problems, which is why our verdict is “consider with safeguards,” not “trust without checking.”

Is MEDVi FDA approved?

FDA does not approve telehealth platforms. MEDVi's compounded semaglutide and tirzepatide products are not FDA-approved finished drugs. If a clinician prescribes an actual named brand such as Wegovy or Zepbound, that branded product has its own FDA approval and label.

Did MEDVi get an FDA warning letter?

Yes. FDA issued Warning Letter #721455 to MEDVi, LLC dba MEDVi on February 20, 2026 over false or misleading marketing of compounded semaglutide and tirzepatide. We found no published close-out letter as of August 6, 2026.¹

Did FDA shut MEDVi down?

No. The warning letter did not announce a shutdown, recall, criminal conviction or contaminated lot. It addressed marketing and misbranding concerns and warned of possible enforcement if the stated violations were not corrected.

How much does MEDVi cost after the first month?

MEDVi's standard semaglutide page says $179 for the first billing cycle and $299 for refills. A separate official price-lock page contains conflicting lower figures, and MEDVi's Terms allow the final charge to vary. Confirm the exact first charge, recurring charge and billing cadence at checkout.^{5 6 4}

Why does MEDVi have an F rating from the BBB?

BBB currently gives MEDVi an F and lists 682 complaints, including 100 unanswered complaints. MEDVi is not BBB accredited. The rating concerns BBB's business and complaint-handling factors; it is not a medication-safety or effectiveness score.²

How do I cancel MEDVi?

MEDVi's current policy says to email hello@medvi.org or use patient-portal chat. The request must be received at least 72 hours before the next billing date to avoid the next charge under the posted rule. The policy does not describe a self-serve cancellation button. Save timestamped proof.³

Can I get a refund from MEDVi?

Only in limited situations under the current policy. These include an early cancellation inside the first 72 hours when no services were received, medical disqualification and certain unused prepaid months. Monthly charges are generally not refunded for the current or prior month.³

Does MEDVi really have a money-back guarantee?

Not in the broad “try it and get everything back if it does not work” sense. MEDVi's current written policy lists specific refund situations. Read the cancellation policy and Terms together, and do not rely on a third-party guarantee summary.

What pharmacy does MEDVi use?

MEDVi currently names Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding. That list does not tell you which pharmacy will fill your individual order. Ask for the exact pharmacy, then verify its license and authority to ship into your state.¹²

Does MEDVi use licensed doctors?

MEDVi names CareGLP Affiliated P.C.s and OpenLoop Health as medical-care networks and says an affiliated clinician makes the prescribing decision. Verify the assigned clinician's full name and active state license rather than relying only on the network description.¹²

Does MEDVi take insurance?

MEDVi's Terms describe affiliated medical entities as out of network, and its main compounded path is cash-pay. MEDVi also displays separate brand options, but coverage and reimbursement depend on the exact product and plan. If insurance matters, check it before choosing cash-pay.

Can I use HSA or FSA funds with MEDVi?

MEDVi markets HSA/FSA eligibility. Your account administrator controls whether a specific charge qualifies and what documentation is needed. Save the prescription and itemized receipt.

Is MEDVi available in my state?

MEDVi's Terms say services are available in certain states and direct people to customer service for the current list. Availability can depend on the product, visit method, clinician and pharmacy. Confirm your exact path during intake.⁴

Is compounded semaglutide legal in 2026?

It can be legal when the prescription, patient need and pharmacy meet current federal and state compounding rules. The broad shortage-based period for routine copies has ended. Patient-specific compounding remains possible under applicable law, but price alone does not create the required clinical difference.²²

Is any oral tirzepatide FDA-approved?

No oral tirzepatide product is FDA-approved as of August 6, 2026. FDA-approved tirzepatide products such as Zepbound are injections. Wegovy tablet is oral semaglutide, and Foundayo is oral orforglipron — neither is oral tirzepatide.^{9 10 11}

Are MEDVi's oral tirzepatide tablets effective?

This page cannot establish that. A pending federal complaint against OpenLoop and Triad Rx alleges an inadequate absorption pathway for the oral tirzepatide product at issue; defendants dispute the case and have moved to dismiss or compel arbitration. Ask the prescriber what exact formulation, absorption method and evidence support the product you are offered.^{13 14}

What happens if the clinician does not approve me?

MEDVi's refund policy says a customer who is medically disqualified by the healthcare provider receives a refund. That is different from changing your mind after a monthly cycle has been charged.³

Is MEDVi safe?

No review page can give MEDVi a blanket “safe” label for every patient and product. The FDA warning letter was about marketing, not a finding that every MEDVi medication was unsafe. But compounded products are not FDA-approved as finished drugs, and FDA has documented broader category risks such as dosing errors, concentration differences, warm shipments and fraudulent labels. Medical fit depends on the exact patient, product, prescriber and pharmacy.^{1 19}

Is MEDVi worth it?

It may be worth considering if you are paying cash, accept a compounded route, verify the exact product and pharmacy, can afford the real recurring charge and will manage the billing deadlines. It is not worth forcing if FDA-approved medication, insurance support, easy refunds, one clear price or a clean complaint record matters more.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz.

Answer five quick questions about your insurance, budget and whether you want an FDA-approved or cash-pay route. You will see the path that fits your situation. No email is required to see the result, and a licensed clinician makes every treatment decision.

→ Get my personalized GLP-1 action plan

How this page was made

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not a medical provider, and nothing here is medical advice.

Who wrote it: the Weight Loss Provider Guide Editorial Team. No clinician reviewed this page, and we're not going to pretend one did. What we did is read documents, compare records and show our work.

How we made it: we checked FDA Warning Letter #721455; MEDVi's current Terms, cancellation policy, public response, standard offer, price-lock page, pharmacy disclosures and AI-content disclaimer; the Newark, Delaware BBB profile; current Trustpilot and ConsumerAffairs profiles; two federal dockets; the OpenLoop breach notice; FDA's current compounding guidance; FDA labels for Wegovy, Foundayo and Zepbound; and current Ro and Embody pages used in the alternatives section.

We compared sources against each other. Where MEDVi's own pages conflicted, we showed the conflict. Where a fact was patient-specific, we labeled it. Where we could not verify a claim from a reliable current source, we removed it instead of filling the gap.

Why it exists: because “is this company real?” and “is this the right company, product and contract for me?” are two different questions. This page answers both.

What we did not do: we did not enroll, submit payment, receive medication, inspect a shipment, lab-test a vial, verify every clinician or pharmacy license, or decide whether treatment is medically appropriate for any reader.

Found something that changed? Prices move, policies get edited and complaint counts change. Send us the source through our corrections page. We will verify it, update material facts and record meaningful changes.

Last verified: August 6, 2026.

Primary sources